RxDoctor Payments Data

Nirmala Ramadhar Persaud, MD

Internal Medicine · Meriden, CTNPI 1801872528

Payments from drug & device makers

$964in general payments, 2019–2025

Across 56 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$218
  • Amgen$142
  • AbbVie$85
  • AstraZeneca$83
  • Lilly USA, LLC$70
  • Takeda Pharmaceuticals U.S.A., Inc.$57
  • plus $307 from 12 others

What the payments were for

  • Food & beverage$964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$964 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$113,951
Medicare patients
202
Services billed
2,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$146,736
JardianceEmpagliflozin73$126,500
XareltoRivaroxaban55$74,048
OzempicSemaglutide36$56,822
RybelsusSemaglutide20$38,037
JanuviaSitagliptin Phosphate44$36,005
ProliaDenosumab19$32,978
MounjaroTirzepatide28$29,767
TrintellixVortioxetine Hydrobromide22$28,919
FarxigaDapagliflozin Propanediol28$24,382
Repatha SureclickEvolocumab25$23,276
TrulicityDulaglutide15$22,050
OxycontinOxycodone Hcl19$17,813
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,784
TradjentaLinagliptin14$13,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$16$148,913152 claims
Boehringer IngelheimJardiance, Tradjenta$218$140,13487 claims
Novo NordiskOzempic, Rybelsus$44$94,85956 claims
Johnson & JohnsonXarelto$24$74,04855 claims
Lilly USA, LLCMounjaro, Trulicity$70$51,81743 claims
MerckJanuvia$28$36,00544 claims
AmgenProlia$142$32,97819 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$57$28,91922 claims
AstraZenecaFarxiga, Symbicort$83$27,66842 claims
GSKTrelegy Ellipta$22$15,78418 claims
AbbVieLinzess, Synthroid$85$12,11465 claims
Astellas Pharma US IncMyrbetriq$20$10,55016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →